In this 8-week , multicenter , randomized , double-blind , placebo-controlled trial , adult outpatients ( aged 18-75 years ) with a primary diagnosis of MDD ( DSM-IV criteria ) were randomly assigned to treatment with desvenlafaxine ( 100-200 mg/day ) or placebo .
